SUMMARY. Cytogenetic studies were performed in bone marrow cells of 24 patients in the relapse of acute lymphoblastic leukemia (ALL), admitted to the laboratory during 2012–2022. A significant percentage of mosaic karyotypes (75.0 %) was noted, among which the combination of an abnormal clone and a normal karyotype (33.3 %) dominated. Trisomies of chromosomes led to the formation of hyperdiploid clones, among which trisomies of chromosomes 6, 21, 15 and 5 were most often found. Most often, additional marker chromosomes were recorded (22.2 %). According to the mechanisms of formation of abnormal clones in the relapses of ALL, structural abnormalities of chromosomes were recorded, among which balanced (translocations, inversions) and unbalanced (deletions, isochromosomes, additional material of unknown origin, duplications, unbalanced translocations) were determined. Losses of genetic material (deletions) (24.1 %) and translocation (33.3 %) were more often detected. The total number of cases with translocation t(9;22)(q34;q11.2) was 20.4 %. The evolution of clonal chromosome abnormalities was due to the appearance of additional quantitative and unbalanced structural abnormalities. Comparison of chromosome abnormalities at diagnosis and relapse in B-ALL did not reveal common mechanisms for the formation of chemotherapy resistant clones. Trisomy of chromosome 5, deletion del(6)(q23), and translocation t(9;22)(q34;q11.2) were involved in the formation of clones that were insensitive tochemotherapy. The group of unfavorable prognosis included 95.8 % of karyotypes.
Keywords: acute lymphoblastic leukemia, relapses, quantitative and structural chromosome abnormalities

Full text and supplemented materials
Free full text: PDFReferences
Andreieva, S., Korets, K., and Skorokhod, I., Cytogenetic characteristics types of variant translocation t(9;22) (q34;q11) in patients at diagnosis of chronic myeloid leukemia, in Hematology and Blood Transfusion: Interdepartmental Collection, 2021, vol. 41, pp. 24–37. https://igt.in.ua/upload/pdf/UA_GPK_41.pdf
Arniani, S., Pierini, V., Pellanera, F., et al., Chromotripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adult, Leukemia, 2022, vol. 36, no. 11, pp. 367–2585. https://doi.org/10.1038/s41375-022-01671-
Atlas of Genetics and Cytogenetics in Oncology and Haematology, Instit. for Biomed. Res. of Salamanca. https://atlasgeneticsoncology.org.
Ben-David, U. and Amon, A., Context is everything: aneuploidy in cancer, Nat. Rev. Genet., 2022, vol. 21, no. 1, pp. 4–62. https://doi.org/10.1038/s41576-019-0171-x
Bochtler, T., Granzow, M., Stolzel, F, et al., Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia, Blood, 2017, vol. 129, no. 10, pp. 1333–1342. https://doi.org/10.1182/blood-2016-09-738161
Galuzzi, L., Vitale, I., Aaronson, S., et al., Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death, Cell Death Differ., 2018, vol. 25, pp. 486–541. https://doi.org/10.1038/s41418-017-0012-4
Gómez-Miragaya, J., Díaz-Navarro, A., Tonda, R., et al., Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity, Cancer Res., 2019, vol. 79, no. 16, pp. 4258–4270. https://doi.org/10.1158/0008-5472.CAN-18-3835
Guideline 00328. Acute Leukemia in Adults, Ministry of Health of Ukraine, 2017. http://guidelines.moz.gov.ua/ documents/ 2918?id=ebm00328&format=pd.
Haddad, F. and Short, N., Evidence-based minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?, Hematol. Am. Soc. Hematol. Educ. Program, 2022, vol. 2022, no.1, pp. 213–217. https://doi.org/10.1182/hematology.2022000413
Haddad, F., Sawyers, J., and Short, N., Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens, Ther. Adv. Hematol., 2023, vol. 14, p. 20406207231151294. https://doi.org/10.1177/20406207231151294
Harvey, R. and Tasian, S., Clinical diagnostic and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia, Blood Adv., 2020, vol. 4, no. 1, pp. 218–228. https://doi.org/10.1182/bloodadvances.2019000163
Heng, H., Bremer, S., Stevens, J., et al., Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution, Cancer Metastasis Rev., 2013, vol. 32, pp. 325–340. https://doi.org/10.1007/s10555-013-9427-7
Hoelzer, D., Bassan, R., Dombret, H., et al., Acute lymphoblastic leukemia in adult patients: ESMO clinical Practice Guidelines for diagnosis, treatment and follow up, Haematol. Malig., 2016, vol. 27, no. 5, pp. 69–82. https://doi.org/10.1093/annonc/mdw025
Kantarjian, H., Short, J., Jain, N., et al., Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-month follow-up results, Am. J. Hematol., 2023, vol. 98, no. 3, pp. 493–501. https://doi.org/10.1002/ajh.26816
McBride, A., Houtmann, S., Wilde, L., et al., The role of inhibitors of apoptosis in acute leukemias and myelodysplastic syndrome, Front. Oncol., 2019, vol. 2, no. 9, p. 192. https://doi.org/10.3389/fonc.2019.00192
McGowan-Jordan, J., Hastings, R., and Moore, S., International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr, Cytogenet. Genome Res., 2021, vol. 161, pp. 225–226.
NCCN Clinical Practice Guidelines in Oncology (2023) NCCN Evidence Blocks. Acute lymphoblastic leukemia 2.202. https://www.nccn.org/professionals/physician_gls/pdf/all_blocks.pd.
Roberts, K., Genetics and prognosis of ALL in children vs adults, Hematol. Am. Soc. Hematol. Educ. Program, 2018, vol. 2018, no. 1, pp. 13–145. https://doi.org/10.1182/asheducation-2018.1.137
Rooney, D. and Czepulkovsky, B., Human Cytogenetics. A Practical Approach. Malignancy and Acquired Abnormalities, Oxford, 1995.
Vargas-Rondon, N., Villegas, V., and Rondon-Lagos, M., The role of chromosomal instability in cancer and therapeutic responses, Cancers (Basel), 2018, vol. 10, no. 1. p. 4. https://doi.org/10.3390/cancers10010004
Wanl, L., Wu, C., Rajasekaran, N., et al., Loss of tumor suppressor gene function in human cancer: an overview, Cell Physiol. Biochem., 2018, vol. 51, pp. 264–2693. https://doi.org/10.1159/00049595